Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery... see more

CSE:SONA - Post Discussion

Sona Nanotech Inc > ANALYSIS OF SAUDI VAC RESULTS
View:
Post by whatdoiknow123 on Sep 01, 2020 1:32pm

ANALYSIS OF SAUDI VAC RESULTS

I usually disagree with MikeyH because he is often very negative, however today he does raise some interesting questions in respect to the apparent inconsistencies reported by Saudi Vac today between the Sensitivities of the Symptomatic and the Asymptomatic Covid positive patients. His argument would be:  why does the Sona test pick up 100% of the Asymptomatic patients but only 83.3% of the Symptomatic ? (still within FDA guidelines by the way) and the suggestion would be that the Sona test is not reliable enough. A reasonable conclusion at face value.

It is, however not quite as simple as that, and the clue may be revealed in that the Symptomatic patients were all hospitalised.

There was a very interesting article published in the NY Times on Aug 29th which referenced DR Michael Mina, expert Harvard Epidemiologist , among others and you should read the whole article if you are interested enough, as it addresses this very theme, but I have included a few quotes below:

"Some of the nation’s leading public health experts are raising a new concern in the endless debate over coronavirus testing in the United States: The standard tests are diagnosing huge numbers of people who may be carrying relatively insignificant amounts of the virus."

"Most of these people are not likely to be contagious, and identifying them may contribute to bottlenecks that prevent those who are contagious from being found in time. But researchers say the solution is not to test less, or to skip testing people without symptoms, as recently suggested by the Centers for Disease Control and Prevention."

"Tests with thresholds so high may detect not just live virus but also genetic fragments, leftovers from infection that pose no particular risk — akin to finding a hair in a room long after a person has left, Dr. Mina said."

"In Massachusetts, from 85 to 90 percent of people who tested positive in July with a cycle threshold of 40 would have been deemed negative if the threshold were 30 cycles, Dr. Mina said. “I would say that none of those people should be contact-traced, not one,” he said."

The suggestion is that patients who have had Covid for prolonged time ( eg. those hospitalised as in the Sona trial) may not still have active infection but have genetic RNA fragments hanging around which are detected by the very accurate PCR machines but have no clinical relevance and that these patients are no longer infectious and cannot pass on the virus. This argument, which has been made before and is gathering force, would adequately and exactly explain why Sona picked up 100% of the Asymptomatics but not some of the possibly long-term hospitalised. This, if confirmed, would be FANTASTIC NEWS for Sona and we should expect to hear more as it would mean that Sona´s test picks up exactly those infected who are responsible for the majority of  the virus spread and doesn´t waste time on the no-longer infectious.

The sample size is acceptable for FDA purposes as they ask for 30 positives and 30 negatives in the total Test Population not in each group. If you were to look for 30 Asymptomatic patients you would probably have to recruit around 500 patients or more and no-one is being asked to do that.
The results reported by Saudi Vac suggest that the Sona test, using the GNRs to increase detection and provide exceptional Sensitivity in Low Viral Loads ie. Asymptomatic patients is exactly what the world needs.

Saudi Vac themselves say that the test is ideal as a Screening Tool for the Saudi Ministry of Health and others are bound to follow. It is the only test, so far, that can claim this and even if the FDA drags its´ heels there will be plenty of demand elsewhere.







 

In Massachusetts, from 85 to 90 percent of people who tested positive in July with a cycle threshold of 40 would have been deemed negative if the threshold were 30 cycles, Dr. Mina said. “I would say that none of those people should be contact-traced, not one,” he said.

Comment by gryphons on Sep 01, 2020 2:09pm
well written,  very insightful,  thank you
Comment by MikeyH on Sep 02, 2020 4:29am
This is a fair post, and I don't disagree with the theory. But the company will need a much larger study to prove it; 3/3 to claim a 100% sensitivity is statistically unacceptable in a clinical setting. If the FDA award EUA on the back of this Saudi study, it will come with stringent user guidance (just like the Abbott test). I guess Sona will then go away and, in addition to trying to start ...more  
Comment by Cottrader on Sep 02, 2020 5:01am
the 90% was from on in field studies not a controlled environment, human error, patient error etc. We got 96.6% in a lab. And the the control group was 40 people not showing symptons but suspected of have covid19 and sonas test accurately picked the 3 out of the 40 that did in fact have it and correctly identified the 37/37 that didn't.
Comment by MikeyH on Sep 02, 2020 5:23am
The lab data DOES NOT MATTER. That was a Sona in-house 30 sample study using denatured protein spiked into known negative swab samples. It's proof that a test might work clinically - nothing more, nothing less. All that matters is the clinical data. And yes, that was generated in a clinical setting, under clinical conditions. This idea that it's somehow is 'uncontrolled' is yet ...more  
Comment by coalnow2 on Sep 02, 2020 5:59am
I read it as the test identified 40/40.  37/37 tested negative - test identitied this  3/3 tested positive - test identified. 
Comment by MikeyH on Sep 02, 2020 6:14am
Absolutely. But correctly identifying a positive is not equivalent to correctly identifying a negative with this type of test. That is why the FDA (and indeed most regulatory bodies) require a minimum number of positives within the dataset to make the study statistically sound. The best illustration is if patient 41 is positive and the Sona test fails to identify this, the sensitivity falls from ...more  
Comment by creesil on Sep 02, 2020 6:58am
Of course it won't be part of the EUA. The FDA isn't assessing and I'm sure hasn't been asked to grant the EUA based on this being an asymptomatic test. It's a rapid antigen test. That can come on the next round with a wider dataset I'm sure but that doesn't impact the sale of this as being the best test in town for picking up asymptomatic patients who are positive ...more  
Comment by merkywaters on Sep 02, 2020 8:16am
Great post creesil. The world is in desparate straits and if we wait for the "perfect" test it will be too late. We need antigen testing and asap. We can refine with time. Cripes...the FDA approved blood plasma! Murk
Comment by whatdoiknow123 on Sep 02, 2020 9:16am
MikeyH, you make some valid points but I think that these can be addressed as follows: 1. "3/3 to claim sensitivity is statistically unacceptable."  First all it was part of an overall study in which the overall Sensitivity was 84.6% which is within FDA Guidelines. Secondly there were only 3 Asymptomatic positives and they identified them all. It identified the only 3 positives ...more  
Comment by Specific on Sep 02, 2020 9:45am
5 star post  whatdoiknow
Comment by shoosh22 on Sep 02, 2020 10:42am
Putting this back to the top.. it is a great post whatdoiknow.. thank you.. We also have HC and EU that we have submitted to..  How many countries does the EU have?  So we will be able to sell there. and the Gufl Countries are about 6..   That's over 25 countries that will be able to sell through their respective authorities..  and there are a lot of countries who do ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities